Clinical-immunological Features of Anti-NMDAR Encephalitis

Active, not recruiting

• Conditions: Anti NMDA Receptor Encephalitis

• Registration Number: NCT05738668
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-01
• Status Verified: 2022-09
• Study First Submitted: 2022-09-05
• Primary Completion: 2022-10-01
• Study First Submitted QC: 2023-02-12
• Last Update Submitted: 2023-02-12
• Study First Posted: 2023-02-22
• Last Update Posted: 2023-02-22
• Study Completion: 2025-02-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

• Patient with neurological disorder
• Patient with NMDAR antibodies in sera or CSF

Exclusion Criteria

• • No available clinical data
• Patient without NMDAR antibodies or neurological disorder

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified Rankin scale (mRS)	Baseline	Scale for measuring the degree of dependence in the daily activities of people who have suffered of neurological disability.; 0 - No symptoms.; 1. - No significant disability. Able to carry out all usual activities, despite some symptoms.; 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.; 3. - Moderate disability. Requires some help, but able to walk unassisted.; 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.; 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.; 6. - Dead.

Trial Locations

Locations (1)

Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est; 🇫🇷 Lyon, Bron, France